Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06314958 · ClinicalTrials.gov registry record
Stage II/III Colorectal Cancer Recurrence
A clinical trial of Colorectal Cancer and Colorectal Adenocarcinoma, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 400
- Enrollment target
- 4
- Study locations
NCT06314958 is a study of Colorectal Cancer and Colorectal Adenocarcinoma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 400 participants, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (74% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT06314958, a study of Colorectal Cancer and Colorectal Adenocarcinoma, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.
Conditions Studied
Interventions
- OTHER CENSURE
Study Locations (4)
Other
- Second Affiliated Hospital of Dalian Medical University - Dalian
- Barcelona University - Barcelona
- La Paz University Hospital - Madrid
California
- City of Hope Medical Center - Monrovia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2026-06-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06314958
The ClinicalTrials.gov registry entry for NCT06314958 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (74% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which CENSURE is the first listed.
NCT06314958 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Other, California.
Frequently Asked Questions
What is clinical trial NCT06314958 about?
NCT06314958 is a clinical study titled "Stage II/III Colorectal Cancer Recurrence". This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.
What is the current status of trial NCT06314958?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2023-03-15. Estimated completion is 2026-06-18.
What conditions does trial NCT06314958 study?
This clinical trial studies the following conditions: Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Recurrent.
What interventions are being tested in trial NCT06314958?
The interventions under investigation include: CENSURE (OTHER).
Who is sponsoring clinical trial NCT06314958?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06314958 being conducted?
This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.